Optiscan Imaging Ltd
ASX:OIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Optiscan Imaging Ltd
Capital Expenditures
Optiscan Imaging Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Capital Expenditures
-AU$250.3k
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
-38%
|
|
|
Somnomed Ltd
ASX:SOM
|
Capital Expenditures
-AU$6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Capital Expenditures
-AU$2.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-12%
|
|
|
Cochlear Ltd
ASX:COH
|
Capital Expenditures
-AU$99m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-11%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Capital Expenditures
-AU$5.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Capital Expenditures
-AU$78.3k
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Optiscan Imaging Ltd
Glance View
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The company is headquartered in Mulgrave, Victoria. The firm has developed and commercialized confocal microscopes for clinical and pre-clinical applications. Its endomicroscopic technology enables 3D, in-vivo imaging of human tissue at the cellular level for cancer screening, diagnoses and in surgery. Its InVivage device is developed for clinical use in the oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a miniaturised confocal endomicroscope used for cellular level in-vivo imaging in living tissues. The firm also provides customization options for its product, (FIVE2).
See Also
What is Optiscan Imaging Ltd's Capital Expenditures?
Capital Expenditures
-250.3k
AUD
Based on the financial report for Dec 31, 2025, Optiscan Imaging Ltd's Capital Expenditures amounts to -250.3k AUD.
What is Optiscan Imaging Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-38%
Over the last year, the Capital Expenditures growth was -279%. The average annual Capital Expenditures growth rates for Optiscan Imaging Ltd have been -1% over the past three years , -56% over the past five years , and -38% over the past ten years .
